Adaptive clinical trial design

Annual Review of Medicine

Volumn 65, Issue , 2014, Pages 405-415

  Chow, Shein Chung ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adaptive dose finding design; Group sequential design; Phase I II adaptive seamless design

Indexed keywords

BIOLOGICAL MARKER;

ADAPTATION; BAYES THEOREM; BREAST CANCER; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DECISION MAKING; DISEASE COURSE; DOSE CALCULATION; DOSE RESPONSE; DRUG INDUSTRY; EFFECT SIZE; EXTRACORPOREAL OXYGENATION; FOOD AND DRUG ADMINISTRATION; HUMAN; MAXIMUM TOLERATED DOSE; MEDICAL PRACTICE; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REVIEW; SAMPLE SIZE; STUDY DESIGN; TREATMENT DURATION;

CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; RESEARCH DESIGN; STATISTICS AS TOPIC;

EID: 84899999885     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-092012-112310     Document Type: Review

References (48)

1. US Food and Drug Administration. 2004. Innovation or stagnation: challenges and opportunity on the critical path to new medical products. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/ CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm113411.pdf
2. European Medicines Agency. 2006. Methodological issues in confirmatory clinical trials with flexible design and analysis plan. Reflection pap., Committee for Medicinal Products forHuman Use. CPMP/EWP/2459/02, London, UK
3. Chow SC. 2006. Adaptive design methods in clinical trials. Int. Chin. Stat. Assoc. Bull. Jan.: 37-41
4. Chow SC, Chang M. 2008. Adaptive design methods in clinical trials-a review. Orphanet J. Rare Dis. 3:11
5. Chow SC, Chang M. 2011. Adaptive Design Methods in Clinical Trials. New York, NY: Chapman & Hall/CRC. 2nd ed.
6. Chow SC, Chang M, Pong A. 2005. Statistical consideration of adaptivemethods in clinical development. J. Biopharm. Stat. 15:575-91
7. Chow SC, Corey R. 2011. Benefits, challenges and obstacles of adaptive designs in clinical trials. Orphanet J. Rare Dis. 6:79
8. US Food and Drug Administration. 2010. Draft Guidance for Industry-Adaptive Design Clinical Trials for Drugs and Biologics. Rockville, MD: US Food Drug Admin.
9. Gallo P, Chuang-Stein C, Dragalin V, et al. 2006. Adaptive design in clinical drug development-an executive summary of the PhRMA Working Group (with discussions). J. Biopharm. Stat. 16:275-83
10. Thall PF, Simon R, Ellenberg SS. 1989. A two stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 45:537-47 (Pubitemid 19165264)
11. European Agency for the Evaluation ofMedicinal Products. 2002. Point to consider on "Methodological issues in confirmatory clinical trials with flexible design and analysis plan, " Committee for Medicinal Products for Human Use, CPMP/EWP/2459/02, London, UK
12. Bartlett RH, Roloff DW, Cornell RG, et al. 1985. Extracorporeal circulation in neonatal respiratory failure: a prospective randomized study. Pediatrics 76:479-87 (Pubitemid 15248220)
13. Mugford M, Elbourne D, Field D. 2008. Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants. Cochrane Database Syst. Rev. 3:CD001340
14. Gould AL. 1992. Interim analyses for monitoring clinical trials that do not materially affect the type I error rate. Stat. Med. 11:55-66
15. Gould AL. 1995. Planning and revising the sample size for a trial. Stat. Med. 14:1039-51
16. Shih WJ. 1992. Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Common Stat. Theory Methodol. 21:2833-53
17. Bauer P, Köhne K. 1996. Evaluation of experiments with adaptive interim analyses. Biometrics 52:380
18. Cui L, Hung HMJ, Wang SJ. 1999. Modification of sample size in group sequential trials. Biometrics 55:853-57 (Pubitemid 29427088)
19. Proschan MA. 2005. Two-stage sample size re-estimation based on a nuisance parameter: a review. J. Biopharm. Stat. 15:539-74
20. Cohen A, Sackrowitz HB. 1989. Exact tests that recover interblock information in balanced incomplete block design. J. Am. Stat. Assoc. 84:556-59
21. Sampson AR, SillMW.2005. Drop-the-loser design: normal case (with discussions). Biometrical J. 47:257- 81
22. Thall PF, Simon R, Ellenberg SS. 1988. Two-stage selection and testing designs for clinical trials. Biometrika 75:303-10
23. Pong A. 2007. Guest-editor's note: statistical issues in adaptive design methods in clinical trials. J. Biopharmaceut. Stat. 17:1133-34
24. Storer BE. 1989. Design and analysis of phase I clinical trials. Biometrics 45:925-37 (Pubitemid 19249331)
25. O'Quigley J, Pepe M, Fisher L. 1990. Continual reassessment method: a practical design for Phase 1 clinical trials in cancer. Biometrics 46(1):33-48 (Pubitemid 20245604)
26. Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS. 2000. Phase I clinical trial design in cancer drug development. J. Clin. Oncol. 18(3):684-92
27. Iasonos A, Wilton AS, Riedel ER, et al. 2008. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clin. Trials 5(5):465- 77
28. Biomarkers Definitions WorkingGroup. 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 1 69:89-95
29. Freidlin B, Korn EL. 2010. Biomarker-adaptive clinical trial designs. Pharmacogenomics 11(12):1679-82
30. Charkravarty A. 2005. Regulatory aspects in using surrogate markers in clinical trials. In The Evaluation of Surrogate Endpoints, ed. T Burzykowski, G Molenberghs, M Buyse. New York: Springer
31. Wang SJ, O'Neill RT, Hung HM. 2007. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm. Stat. 6(3):227-44
32. Freidlin B, McShane L, Korn EL. 2010. Randomized clinical trials with biomarkers: design issues. J. Natl. Cancer Inst. 102(3):152-60
33. Sargent DJ, Conley BA, Allegra C, Collette L. 2005. Clinical trial designs for predictivemarker validation in cancer treatment trials. J. Clin. Oncol. 23:2020-27
34. Simon R. 2005. Roadmap for developing and validating therapeutically relevant genomic classifiers. J. Clin. Oncol. 23:7332-41
35. Branson M, Whitehead J. 2002. Estimating a treatment effect in survival studies in which patients switch treatment. Stat. Med. 21:2449-63
36. Shao J, Chang M, Chow SC. 2005. Statistical inference for cancer trials with treatment switching. Stat. Med. 24:1783-90
37. White IR. 2006. Letter to the editor: estimating treatment effects in randomized trials with treatment switching. Stat. Med. 25:1619-22
38. Maca J, Bhattacharya S, Dragalin V, et al. 2006. Adaptive seamless phase II/III designs-background, operational aspects, and examples. Drug Info. J. 40:463-74
39. Berry SM, Carlin BP, Lee JJ, Muller P. 2011. Bayesian Adaptive Methods for Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC Press
40. Berry DA, Eick SG. 1995. Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. Stat. Med. 14:231-46
41. Berry DA, Stangl DK. 1996. Bayesian Biostatistics. New York: Marcel Dekker
42. Gelman A, Carlin JB, Stein H, RubinDB. 2003. Bayesian Data Analysis.New York:Chapman&Hall/CRC Press. 2nd ed.
43. Spiegelhalter DJ, Abrams KR, Myles JP. 2004. Bayesian Approach to Clinical Trials and Health-care Evaluation. Chichester, UK:Wiley
44. US Food andDrug Administration. 2010. Guidance for the Use of Bayesian Statistics inMedical Device Clinical Trials. Rockville, MD: US FDA
45. Lai TL, Lavori PW, Shih MC. 2011. Adaptive trial designs. Annu. Rev. Pharmacol. Toxicol. 52:101-10
46. Chow SC, Corey R, LinM. 2012. On the independence of data monitoring committee in adaptive design clinical trials. J. Biopharm. Stat. 22:853-67
47. Quinlan JA, Krams M. 2006. Implementing adaptive designs: logistical and operational considerations. Drug Inf. J. 40(4):437-44 (Pubitemid 44721121)
48. Woodcock J. 2005. FDA introduction comments: clinical studies design and evaluation issues. Clin. Trials 2:273-75 (Pubitemid 41306266)